Antonio Cuadrado

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4045088/publications.pdf

Version: 2024-02-01

114 papers	15,432 citations	16451 64 h-index	21540 114 g-index
116 all docs	116 docs citations	116 times ranked	19407 citing authors

#	Article	IF	Citations
1	Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases. Annual Review of Pharmacology and Toxicology, 2022, 62, 255-277.	9.4	33
2	Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinsonâ€™s Disease. Antioxidants, 2022, 11, 247.	5.1	4
3	Transcription Factor NRF2 Participates in Cell Cycle Progression at the Level of G1/S and Mitotic Checkpoints. Antioxidants, 2022, 11, 946.	5.1	7
4	Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. Free Radical Biology and Medicine, 2022, 187, 72-91.	2.9	28
5	An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter Î²-TrCP delivers anti-inflammatory responses in mouse liver. Redox Biology, 2022, 55, 102396.	9.0	8
6	Î±-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. Molecular Neurobiology, 2021, 58, 6697-6711.	4.0	8
7	Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research, 2020, 152, 104597.	7.1	13
8	Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas. Redox Biology, 2020, 30, 101425.	9.0	26
9	TAZ Represses the Neuronal Commitment of Neural Stem Cells. Cells, 2020, 9, 2230.	4.1	9
10	Inflammation in Parkinsonâ€™s Disease: Mechanisms and Therapeutic Implications. Cells, 2020, 9, 1687.	4.1	334
11	Can Activation of NRF2 Be a Strategy against COVID-19?. Trends in Pharmacological Sciences, 2020, 41, 598-610.	8.7	161
12	Perspectives on the Clinical Development of NRF2-Targeting Drugs. Handbook of Experimental Pharmacology, 2020, 264, 93-141.	1.8	14
13	WIP Modulates Oxidative Stress through NRF2/KEAP1 in Glioblastoma Cells. Antioxidants, 2020, 9, 773.	5.1	4
14	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	16.0	70
15	NRF2 and Primary Cilia: An Emerging Partnership. Antioxidants, 2020, 9, 475.	5.1	8
16	Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases. Frontiers in Pharmacology, 2020, 11, 151.	3.5	55
17	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. European Journal of Medicinal Chemistry, 2020, 190, 112090.	5.5	15
18	Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-20.	4.0	390

#	Article	IF	Citations
19	Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage. Trends in Endocrinology and Metabolism, 2019, 30, 312-327.	7.1	50
20	Emerging Therapeutic Targets in Oncologic Photodynamic Therapy. Current Pharmaceutical Design, 2019, 24, 5268-5295.	1.9	15
21	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery, 2019, 18, 295-317.	46.4	849
22	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	16.0	441
23	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. Antioxidants and Redox Signaling, 2018, 28, 852-872.	5.4	62
24	Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biology, 2018, 14, 522-534.	9.0	125
25	A role for APP in Wnt signalling links synapse loss with Î²-amyloid production. Translational Psychiatry, 2018, 8, 179.	4.8	74
26	Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy, 2018, 14, 1310-1322.	9.1	134
27	Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biology, 2018, 18, 173-180.	9.0	84
28	Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biology, 2017, 11, 543-553.	9.0	147
29	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	9.0	242
30	Discovery of the first dual GSK3Î² inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 45701.	3.3	59
31	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biology, 2017, 13, 444-451.	9.0	161
32	Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus. Redox Biology, 2017, 13, 393-401.	9.0	69
33	Response to I. Batinic-Haberle et al.. Antioxidants and Redox Signaling, 2016, 24, 525-526.	5.4	0
34	Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease. Antioxidants and Redox Signaling, 2016, 25, 61-77.	5.4	209
35	NRF2 in neurodegenerative diseases. Current Opinion in Toxicology, 2016, 1, 46-53.	5.0	19
36	Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy, 2016, 12, 1902-1916.	9.1	300

#	Article	IF	Citations
37	Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice. Molecular Neurobiology, 2016, 53, 3030-3045.	4.0	82
38	Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1â€independent manner. Molecular Nutrition and Food Research, 2015, 59, 1431-1442.	3.3	53
39	WNT-3A Regulates an Axin1/NRF2 Complex That Regulates Antioxidant Metabolism in Hepatocytes. Antioxidants and Redox Signaling, 2015, 22, 555-571.	5.4	50
40	Antioxidants in Translational Medicine. Antioxidants and Redox Signaling, 2015, 23, 1130-1143.	5.4	201
41	Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/Î²-TrCP. Free Radical Biology and Medicine, 2015, 88, 147-157.	2.9	196
42	Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes. Free Radical Biology and Medicine, 2015, 84, 263-278.	2.9	50
43	Clinical Relevance of Biomarkers of Oxidative Stress. Antioxidants and Redox Signaling, 2015, 23, 1144-1170.	5.4	604
44	Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxidants and Redox Signaling, 2015, 23, 1113-1129.	5.4	75
45	Melatoninâ€“sulforaphane hybrid <scp>ITH</scp>12674 induces neuroprotection in oxidative stress conditions by a â€˜drugâ€“prodrugâ€™ mechanism of action. British Journal of Pharmacology, 2015, 172, 1807-1821.	5.4	36
46	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxidants and Redox Signaling, 2015, 23, 1171-1185.	5.4	120
47	Activation of autophagy in macrophages by pro-resolving lipid mediators. Autophagy, 2015, 11, 1729-1744.	9.1	65
48	Redox control of protein degradation. Redox Biology, 2015, 6, 409-420.	9.0	138
49	Agmatine Induces Nrf2 and Protects Against Corticosterone Effects in Hippocampal Neuronal Cell Line. Molecular Neurobiology, 2015, 51, 1504-1519.	4.0	52
50	Nrf2 protects the lung against inflammation induced by titanium dioxide nanoparticles: A positive regulator role of Nrf2 on cytokine release. Environmental Toxicology, 2015, 30, 782-792.	4.0	28
51	Effects of Nrf2 Deficiency on Bone Microarchitecture in an Experimental Model of Osteoporosis. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	4.0	83
52	The PTEN/NRF2 Axis Promotes Human Carcinogenesis. Antioxidants and Redox Signaling, 2014, 21, 2498-2514.	5.4	104
53	Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain, 2014, 137, 78-91.	7.6	112
54	Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance. Antioxidants and Redox Signaling, 2014, 21, 1766-1801.	5.4	261

#	Article	IF	Citations
55	Transcription Factors NRF2 and NF-Î³B Are Coordinated Effectors of the Rho Family, GTP-binding Protein RAC1 during Inflammation. Journal of Biological Chemistry, 2014, 289, 15244-15258.	3.4	262
56	Neuroprotective effect of melatonin against ischemia is partially mediated by alphaâ€7 nicotinic receptor modulation and <scp>HO</scp>â€1 overexpression. Journal of Pineal Research, 2014, 56, 204-212.	7.4	93
57	Protein tyrosine phosphatase 1B modulates GSK3Î²/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death and Disease, 2013, 4, e626-e626.	6.3	75
58	Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology, 2013, 38, 2010-2022.	2.7	108
59	Nuclear Import and Export Signals Control the Subcellular Localization of Nurr1 Protein in Response to Oxidative Stress*. Journal of Biological Chemistry, 2013, 288, 5506-5517.	3.4	57
60	Nrf2 is controlled by two distinct Î²-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene, 2013, 32, 3765-3781.	5.9	500
61	Î±-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics, 2012, 21, 3173-3192.	2.9	228
62	Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/Î²-TrCP Axis. Molecular and Cellular Biology, 2012, 32, 3486-3499.	2.3	338
63	Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radical Biology and Medicine, 2012, 52, 473-487.	2.9	177
64	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Î²-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation, 2012, 9, 8.	7.2	196
65	SCF/Î²-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner. Molecular and Cellular Biology, 2011, 31, 1121-1133.	2.3	647
66	Nrf2 deficiency potentiates methamphetamineâ€induced dopaminergic axonal damage and gliosis in the striatum. Glia, 2011, 59, 1850-1863.	4.9	79
67	Deficiency of Nrf2 Accelerates the Effector Phase of Arthritis and Aggravates Joint Disease. Antioxidants and Redox Signaling, 2011, 15, 889-901.	5.4	93
68	Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism. Antioxidants and Redox Signaling, 2011, 14, 2347-2360.	5.4	271
69	Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Molecular Pharmacology, 2011, 79, 964-973.	2.3	305
70	Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: Modulation by the Nrf2/Trx axis. Free Radical Biology and Medicine, 2010, 48, 1370-1381.	2.9	120
71	The purinergic P2Y13 receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radical Biology and Medicine, 2010, 49, 416-426.	2.9	68
72	Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 2010, 58, 588-598.	4.9	301

#	Article	IF	Citations
73	Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1. PLoS ONE, 2010, 5, e11838.	2.5	118
74	Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases. Current Drug Targets, 2010, 11, 1517-1531.	2.1	192
75	Haeme oxygenase-1 overexpression via nAChRs and the transcription factor Nrf2 has antinociceptive effects in the formalin test. Pain, 2009, 146, 75-83.	4.2	21
76	Heme oxygenase-1 induction modulates microsomal prostaglandin E synthase-1 expression and prostaglandin E2 production in osteoarthritic chondrocytes. Biochemical Pharmacology, 2009, 77, 1806-1813.	4.4	39
77	The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSKâ€3beta: connecting neurotransmission with neuroprotection. Journal of Neurochemistry, 2009, 110, 1107-1119.	3.9	55
78	The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opinion on Therapeutic Targets, 2009, 13, 319-329.	3.4	119
79	Role of microglial redox balance in modulation of neuroinflammation. Current Opinion in Neurology, 2009, 22, 308-314.	3.6	100
80	GSKâ€3Î² downâ€regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. Journal of Neurochemistry, 2008, 105, 192-202.	3.9	208
81	Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal celldeath. Molecular and Cellular Neurosciences, 2008, 39, 125-132.	2.2	112
82	Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress. Neuroscience Letters, 2008, 447, 167-171.	2.1	56
83	Nrf2-mediated haeme oxygenase-1 up-regulation induced by cobalt protoporphyrin has antinociceptive effects against inflammatory pain in the formalin test in mice. Pain, 2008, 137, 332-339.	4.2	52
84	The Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation. Journal of Immunology, 2008, 181, 680-689.	0.8	424
85	Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections. Current Pharmaceutical Design, 2008, 14, 429-442.	1.9	152
86	Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-Jun N-terminal kinase and p38 mitogen-activated protein kinases. Journal of Hypertension, 2007, 25, 609-618.	0.5	25
87	Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Experimental Neurology, 2007, 208, 120-126.	4.1	71
88	Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. Journal of Neurochemistry, 2007, 102, 1842-1852.	3.9	57
89	Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. European Journal of Neuroscience, 2006, 24, 1874-1884.	2.6	49
90	Regulation of heme oxygenase-1 gene expression through the phosphatidylinositol 3-kinase/PKC-Î¶ pathway and Sp1. Free Radical Biology and Medicine, 2006, 41, 247-261.	2.9	51

#	Article	IF	Citations
91	Glycogen Synthase Kinase-3Î² Inhibits the Xenobiotic and Antioxidant Cell Response by Direct Phosphorylation and Nuclear Exclusion of the Transcription Factor Nrf2. Journal of Biological Chemistry, 2006, 281, 14841-14851.	3.4	441
92	Inhibition of Heme Oxygenase-1 Interferes with the Transforming Activity of the Kaposi Sarcoma Herpesvirusencoded G Protein-coupled Receptor. Journal of Biological Chemistry, 2006, 281, 11332-11346.	3.4	70
93	Interleukin-1Î² Enhances GABAA Receptor Cell-surface Expression by a Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2006, 281, 14632-14643.	3.4	111
94	Signaling through the Leukocyte Integrin LFA-1 in T Cells Induces a Transient Activation of Rac-1 That Is Regulated by Vav and PI3K/Akt-1. Journal of Biological Chemistry, 2004, 279, 16194-16205.	3.4	58
95	Regulation of Cu/Zn-Superoxide Dismutase Expression via the Phosphatidylinositol 3 Kinase/Akt Pathway and Nuclear Factor-ÎºB. Journal of Neuroscience, 2004, 24, 7324-7334.	3.6	194
96	Regulation of Heme Oxygenase-1 Expression through the Phosphatidylinositol 3-Kinase/Akt Pathway and the Nrf2 Transcription Factor in Response to the Antioxidant Phytochemical Carnosol. Journal of Biological Chemistry, 2004, 279, 8919-8929.	3.4	642
97	Protein kinase Akt/PKB phosphorylates heme oxygenaseâ€1 in vitro and in vivo. FEBS Letters, 2004, 578, 90-94.	2.8	97
98	Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104, 619-625.	1.4	158
99	Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner. Journal of Biological Chemistry, 2003, 278, 13898-13904.	3.4	238
100	Ceramide and Reactive Oxygen Species Generated by H2O2 Induce Caspase-3-independent Degradation of Akt/Protein Kinase B. Journal of Biological Chemistry, 2002, 277, 42943-42952.	3.4	160
101	Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-ÎºB through an AKT/P70S6K/p38-MAPK pathway. Oncogene, 2002, 21, 3739-3753.	5.9	60
102	Akt1/PKBÎ± Protects PC12 Cells against the Parkinsonism-Inducing Neurotoxin 1-Methyl-4-phenylpyridinium and Reduces the Levels of Oxygen-Free Radicals. Molecular and Cellular Neurosciences, 2001, 17, 67-77.	2.2	54
103	Effect of the Alzheimer amyloid fragment AÎ²(25â€“35) on Akt/PKB kinase and survival of PC12 cells. Journal of Neurochemistry, 2001, 78, 1000-1008.	3.9	142
104	Inhibition of PKB/Akt1 by C2-Ceramide Involves Activation of Ceramide-Activated Protein Phosphatase in PC12 Cells. Molecular and Cellular Neurosciences, 2000, 15, 156-169.	2.2	183
105	Activation of Akt/Protein Kinase B by G Protein-coupled Receptors. Journal of Biological Chemistry, 1998, 273, 19080-19085.	3.4	303
106	Uneven distribution of protein kinase C-? and -? isozymes in human sarcomas and carcinomas. Journal of Cellular Physiology, 1994, 159, 434-440.	4.1	5
107	Acylphosphatase synergizes with progesterone during maturation ofXenopus laevisoocytes. FEBS Letters, 1993, 327, 265-270.	2.8	6
108	The probability of G1 cells to enter into S increases with their size while S length decreases with cell enlargement in Allium cepa. Experimental Cell Research, 1990, 191, 163-170.	2.6	9

#	Article	IF	Citations
109	Expression of protein kinase C I in NIH 3T3 cells increases its growth response to specific activators. FEBS Letters, 1990, 260, 281-284.	2.8	16
110	Increased tyrosine phosphorylation in rat transformed fibroblasts occurs prior to manifestation of the transformed phenotype. Biochemical and Biophysical Research Communications, 1990, 170, 526-532.	2.1	4
111	Cell size of proliferating plant cells increases with temperature: Implications in the control of cell division. Experimental Cell Research, 1989, 185, 277-282.	2.6	11
112	Influence of cell size on differentiation of root meristem cells. Environmental and Experimental Botany, 1987, 27, 273-277.	4.2	5
113	Partial elimination of G1 and G2 periods in higher plant cells by increasing the S period. Experimental Cell Research, 1983, 148, 273-280.	2.6	25
114	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. SSRN Electronic Journal, 0, , .	0.4	0